Salarius Pharmaceuticals focuses on developing treatments for cancers with unmet medical needs. Their lead candidate, Seclidemstat, is in Phase I/II trials for advanced solid tumors and Ewing sarcoma. They also offer SP-3164 for hematological and solid tumors.